Your browser doesn't support javascript.
loading
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study.
Lemaitre, Florian; Fily, Fabien; Foulquier, Jean-Baptiste; Revest, Matthieu; Jullien, Vincent; Petitcollin, Antoine; Tattevin, Pierre; Tron, Camille; Polard, Jean-Louis; Verdier, Marie-Clémence; Comets, Emmanuelle; Huten, Denis; Arvieux, Cédric; Bellissant, Eric; Laviolle, Bruno.
Afiliación
  • Lemaitre F; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France. Electronic address: florian.lemaitre@chu-rennes.fr.
  • Fily F; Epicentre, 55 rue Crozatier, 75012, Paris, France; Infectious Diseases Unit, Broussais Hospital, Saint Malo, France.
  • Foulquier JB; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France.
  • Revest M; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; University of Rennes, Inserm, BRM (Bacterial Regulatory RNAs and Medicine), UMR, France.
  • Jullien V; University Paris 13, groupe hospitalier Paris Seine-Saint-Denis, Assistance publique-Hôpitaux de Paris, 93000 Bobigny, France; Molecular Mycology Unit-CNRS UMR 2000, Pasteur Institute, 75015 Paris, France.
  • Petitcollin A; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France.
  • Tattevin P; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; University of Rennes, Inserm, BRM (Bacterial Regulatory RNAs and Medicine), UMR, France.
  • Tron C; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France.
  • Polard JL; Department of Orthopaedic Surgery and Traumatology, Pontchaillou University Hospital, 2 Avenue Henri Le Guilloux, 35203 Rennes, France.
  • Verdier MC; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France.
  • Comets E; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France.
  • Huten D; Department of Orthopaedic Surgery and Traumatology, Pontchaillou University Hospital, 2 Avenue Henri Le Guilloux, 35203 Rennes, France.
  • Arvieux C; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; University of Rennes, Inserm, BRM (Bacterial Regulatory RNAs and Medicine), UMR, France; Great West Reference centers for Complex Bone and Joint Infections (CRIOGO), France.
  • Bellissant E; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France.
  • Laviolle B; Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d'Investigation Clinique, CIC 1414, F-35000 Rennes, France.
Biomed Pharmacother ; 142: 112053, 2021 Oct.
Article en En | MEDLINE | ID: mdl-34435591
Fluoroquinolones efficacy depend on both the drug exposure and the level of drug resistance of the bacteria responsible for the infection. Specifically for the Staphylococcus species, which is the microorganism mainly involved in osteoarticular infections (OAI), in-vitro data reported that an AUC/MIC ratio above 115 h maximizes drug efficacy. However, data on OAI patients are lacking and a simple approach to access AUCs is still a clinical issue. We conducted a prospective, single-center study in 30 OAI patients hospitalized in the Rennes University Hospital to model ofloxacin pharmacokinetics and to define a limited sampling strategy (LSS) suitable for ofloxacin and levofloxacin treatments. Modeling was conducted with the Monolix software. The final model was externally validated using levofloxacin data. Monte-Carlo simulations were used to evaluate the probability of target attainment (PTA) of different dosing regimens. Two hundred and ninety-seven (297) ofloxacin concentrations were available for the pharmacokinetic modeling. Ofloxacin pharmacokinetics was best described using a bicompartmental model with a first order elimination, and a transit compartment model absorption. CKD-EPI and sex explained half of ofloxacin pharmacokinetic variability. For LSS, the 0, 1 h and 3 h sampling scheme resulted in the best approach both for BID and TID dosages (R2 adjusted = 91.1% and 95.0%, outliers = 4.8% and 5.0%, respectively). PTA allows choosing the best drug and dosage according to various hypotheses. A simple 3-sample protocol (pre-dose, 1 h after intake and 3 h after intake) to estimate ofloxacin and levofloxacin AUC allows optimal drug dosage for the treatment of osteoarticular infections.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Óseas Infecciosas / Fluoroquinolonas / Artropatías / Antibacterianos Tipo de estudio: Guideline / Health_economic_evaluation / Observational_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Biomed Pharmacother Año: 2021 Tipo del documento: Article Pais de publicación: Francia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedades Óseas Infecciosas / Fluoroquinolonas / Artropatías / Antibacterianos Tipo de estudio: Guideline / Health_economic_evaluation / Observational_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Biomed Pharmacother Año: 2021 Tipo del documento: Article Pais de publicación: Francia